Endoscopic treatment of symptomatic VUR disease after the renal transplantation: analysis of 49 cases.
Adult
Age Factors
Aged
Anuria
/ etiology
Cystoscopy
/ adverse effects
Dextrans
/ administration & dosage
Female
Hematuria
/ etiology
Humans
Hyaluronic Acid
/ administration & dosage
Kidney Transplantation
Male
Middle Aged
Retreatment
Sex Factors
Treatment Outcome
Urinary Tract Infections
/ etiology
Urological Agents
/ administration & dosage
Vesico-Ureteral Reflux
/ therapy
Endoscopic treatment
Renal transplantation
Vesicoureteral reflux
Journal
Clinical and experimental nephrology
ISSN: 1437-7799
Titre abrégé: Clin Exp Nephrol
Pays: Japan
ID NLM: 9709923
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
24
11
2019
accepted:
07
01
2020
pubmed:
20
1
2020
medline:
5
2
2021
entrez:
20
1
2020
Statut:
ppublish
Résumé
To evaluate the outcome of endoscopic treatment for symptomatic vesicoureteral reflux (VUR) disease in renal transplantation patients and to determine the factors that were associated with the success rate of the treatment. A total of 121 symptomatic VUR diseases diagnosed between 2014 and 2018 in 3560 renal transplant patients. The results of 49 VUR cases that presented with febrile urinary tract infection (UTI) and were hospitalized for antibiotic treatment were included in the study. Reflux was detected by voiding cystourethrogram and treatment was performed by endoscopic Deflux® injection. The result of endoscopic treatment was evaluated clinically by 3 months periods. The mean time between transplantation and endoscopic treatment was 59.6 (5-132) months, and the mean follow-up period after the endoscopic treatment was 14 (6-48) months, respectively. The success rate after the first injection was 59.1% (n = 29) and 67.3% (n = 33) after the second injection. One patient developed anuria, one patient febrile UTI and four patients developed minimal macroscopic hematuria after the procedure. Endoscopic treatment of symptomatic VUR in transplanted kidney is a safe and feasible procedure. The amount of bulking agent or duration between the transplantation and diagnosis of VUR does not have any impact on the success of the treatment. However, the younger age of the patients and the female gender seem to have a positive effect on the outcome of the procedure.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate the outcome of endoscopic treatment for symptomatic vesicoureteral reflux (VUR) disease in renal transplantation patients and to determine the factors that were associated with the success rate of the treatment.
METHODS
METHODS
A total of 121 symptomatic VUR diseases diagnosed between 2014 and 2018 in 3560 renal transplant patients. The results of 49 VUR cases that presented with febrile urinary tract infection (UTI) and were hospitalized for antibiotic treatment were included in the study. Reflux was detected by voiding cystourethrogram and treatment was performed by endoscopic Deflux® injection. The result of endoscopic treatment was evaluated clinically by 3 months periods.
RESULTS
RESULTS
The mean time between transplantation and endoscopic treatment was 59.6 (5-132) months, and the mean follow-up period after the endoscopic treatment was 14 (6-48) months, respectively. The success rate after the first injection was 59.1% (n = 29) and 67.3% (n = 33) after the second injection. One patient developed anuria, one patient febrile UTI and four patients developed minimal macroscopic hematuria after the procedure.
CONCLUSIONS
CONCLUSIONS
Endoscopic treatment of symptomatic VUR in transplanted kidney is a safe and feasible procedure. The amount of bulking agent or duration between the transplantation and diagnosis of VUR does not have any impact on the success of the treatment. However, the younger age of the patients and the female gender seem to have a positive effect on the outcome of the procedure.
Identifiants
pubmed: 31955313
doi: 10.1007/s10157-020-01847-2
pii: 10.1007/s10157-020-01847-2
doi:
Substances chimiques
Dextrans
0
Urological Agents
0
deflux
0
Hyaluronic Acid
9004-61-9
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
483-488Références
Clin Transplant. 2004;18 Suppl 11:34-8
pubmed: 15191371
J Urol. 2006 Oct;176(4 Pt 1):1582-7; discussion 1587
pubmed: 16952692
BJU Int. 2011 Jun;107(12):1967-72
pubmed: 21059169
Transplant Proc. 2019 Jun;51(5):1420-1423
pubmed: 31076150
Transplant Proc. 2011 Jun;43(5):1619-22
pubmed: 21693244
J Urol. 1995 Aug;154(2 Pt 2):800-3
pubmed: 7541869
Pediatr Radiol. 1985;15(2):105-9
pubmed: 3975102
Transplant Proc. 2000 Nov;32(7):1844-6
pubmed: 11119965
Ann Urol (Paris). 2007 Dec;41(6):261-75
pubmed: 18457318
J Urol. 2011 Jul;186(1):257-60
pubmed: 21575977
Transplant Proc. 2014 Jun;46(5):1332-9
pubmed: 24935298
J Urol. 2015 Jan;193(1):225-9
pubmed: 25088951
J Urol. 2006 Feb;175(2):716-22
pubmed: 16407037
Prog Urol. 2003 Sep;13(4):598-601
pubmed: 14650289
Transplant Proc. 2010 Oct;42(8):2892-5
pubmed: 20970562
Transplant Proc. 1994 Feb;26(1):292
pubmed: 8108987
Prog Transplant. 2017 Jun;27(2):196-199
pubmed: 28617157
Transpl Int. 2014 Nov;27(11):1152-8
pubmed: 24990577